List view / Grid view
Radiopharmaceuticals represent a rapidly advancing field in oncology, using radioactive compounds to both detect and treat cancer at the molecular level. This article explores how targeted radiation is improving patient outcomes while reducing systemic toxicity.
Scientists have developed a 3D liver model, known as the periportal assembloid. This model replicates the liver’s complex structure and bile transport system, enabling more precise study of disease progression.
Researchers at Texas A&M University have developed advanced vessel-chip technology that closely mimics the complex architecture of human blood vessels, offering a new potential platform for studying vascular diseases and accelerating drug discovery.
Generative AI is broadening the boundaries of what is possible in drug discovery. In this article, Murat Tunaboylu, CEO and Co-founder of Antiverse, reveals how the zeitgeist technology is enabling scientists to tackle previously undruggable targets like GPCRs and ion channels to deliver patient impact faster.
What if a single hormone could control appetite in two entirely different ways? Professor Stefan Trapp of University College London reveals how GLP-1’s dual role in the brain and gut could transform obesity treatment.
Forget the buzzwords - SLAS 2025 showed what’s genuinely driving progress in drug discovery: usable AI, collaborative platforms and tools that solve real problems.
ELRIG has announced the keynote speakers for Drug Discovery 2025, its flagship life sciences event taking place in Liverpool, England this October.
The body undergoes changes with age that can lead to conditions like sarcopenia and osteoarthritis, burdening individuals and healthcare systems. Find out how Rejuvenate Biomed uses AI to decode ageing biology and develop combination therapies targeting the root causes of age-related diseases, offering hope for better treatments and quality of…
K Navigator, a new AI-powered research co-pilot, is set to transform biomedical science by helping researchers explore complex data and accelerate discoveries.
Scientists have developed a new drug, SHP1705, that targets hijacked circadian clock proteins used by glioblastoma stem cells to grow and resist treatment.
CatalYm announces new preclinical data showing that its clinical-stage antibody, visugromab, can overcome resistance to antibody-drug conjugates (ADCs), showing potential to restore anti-tumour immune responses in solid tumours.
Metrion Biosciences has introduced a breakthrough NaV1.9 screening assay, aimed at overcoming historical challenges in pain research and advancing the development of non-opioid treatments.
Cell and gene therapy is rapidly transforming the treatment of complex diseases, yet scaling production efficiently remains a challenge. Dr Tia Harmon from PHC Corporation of North America explores the innovations that are optimising cell expansion to enhance the discovery of advanced therapies.
Researchers at Osaka Metropolitan University have found that plasma-activated medium (PAM) significantly reduces synovial sarcoma tumour growth in both lab and animal models, offering a promising new approach for treating this rare and aggressive cancer.
See how the new Shasta™ Single Cell System enabled high-throughput single-cell DNA-seq library preparation to detect tumor-driving mutations.
